INSIGHT S2414

A RANDOMIZED PHASE III TRIAL INCORPORATING PATHOLOGIC RESPONSE IN PARTICIPANTS WITH EARLY STAGE NON-SMALL CELL LUNG CANCER TO OPTIMIZE IMMUNOTHERAPY IN THE ADJUVANT SETTING

BACKGROUND

PROTOCOL VERSION DATE: 03/11/2025

- Cure rates for patients with early-stage NSCLC remain unacceptably low.
- Use of neoadjuvant chemo-immunotherapy is now an accepted SOC for the treatment of early-stage NSCLC.
- Patients with a pCR have significantly improved outcomes than those with residual cancer.
- It is unclear if patients with pCR benefit from adjuvant immunotherapy.

OBJECTIVES

PRIMARY

- Compare DFS between arms

SECONDARY

- Compare OS between arms
- Evaluate frequency and severity of toxicities of adjuvant durvalumab
- Compare EFS between arms

SCHEMA



Enrolling 306 participants
Opened to accrual 3/14/25

*Local pathology review
**Non-path CR patients may be eligible for ECOG-ACRIN CLEAR (EA5231)

TREATMENT

ARM 1 ONLY

AGENT	DOSE	ROUTE	DAY	SCHEDULE
Durvalumab	1500 mg	IV over 60 minutes	Day 1 of each cycle	28-day cycle for up to 12 cycles

ARMS 1 & 2

PROCEDURE	YEAR 1	YEAR 2	YEAR 3-10
CT scan	Every 12 weeks	Every 6 months	Annually until recurrence

KEY ELIGIBILITY CRITERIA

DISEASE CRITERIA

- Histologically or cytological confirmed diagnosis of clinical Stage II-IIIB NSCLC.
  - Excluding clinical N3 disease.
- R0 resection of NSCLC within 84 days prior to randomization.
  - Acceptable surgical resections: lobectomy, sleeve resection, bi-lobectomy, or pneumonectomy.
  - Wedge resection **not** allowed.
- Pathologic complete response (pCR) determined by **local pathology review**.
- Have PD-L1 status result.
- No known EGFR mutations or ALK gene fusion.

THERAPY CRITERIA

- Received ≥ 2 cycles of neoadjuvant platinum-based chemotherapy.
  - **Any** FDA-approved platinum-based neoadjuvant regimen is accepted.
- Received ≥ 2 cycles of anti-PD-1 or anti-PD-L1 therapy.
- Not planning to receive any concurrent non-protocol directed therapy for NSCLC.
- No systemic therapy within 28 days prior to randomization.
- No medical contraindications or SAEs to receiving anti-PD-1 or anti-PD-L1 therapy.
- No post-operative radiation therapy (PORT) for NSCLC.

CLINICAL/LAB CRITERIA

- ≥ 18 years old.
- Body weight > 30 kg.
- Zubrod Performance Status 0-2.
- Adequate organ and marrow function.
- Creatinine clearance ≥ 40 mL/min.
- Fully recovered from prior surgery.
- No history of organ transplant.
- No prior/concurrent malignancy that could interfere with investigational regimen.
- No medical contraindications to receiving immunotherapy.
  - Intra-articular steroid injections and replacement therapy are allowed.
- Not pregnant or nursing.

Regulatory, Protocol, Informed Consent
protocols@swog.org | (210) 614-8808

Eligibility, RAVE, Data Submission
lungquestion@crab.org | (206) 652-2267

Medical Queries (treatment or toxicity)
S2414MedicalQuery@swog.org

NCI National Clinical Trials Network
SWOG CANCER RESEARCH NETWORK
NCI Community Oncology Research Program